Clinical Trials Logo

Clinical Trial Summary

Literature shows that less than half of advanced cancer patients accurately understand their prognosis, with most being overly optimistic. Investigators suspect that many patients are reporting not what they believe, but what they would like to believe. This study aims to discern patient's beliefs about prognosis independent of hope, to identify factors that influence patient's beliefs, and to explore patient preferences for prognostic information.

Investigators propose to randomize 200 cancer patients with a prognosis of less than one year to receive one of the two versions of a survey. Investigators hypothesize that, although many patients will continue to be overly optimistic about their prognosis, those patients responding to Version 2, followed by Version 1, will provide more accurate estimates.

Efforts to improve decision making require an understanding of patients' beliefs and preferences for receiving prognostic information and identifying strategies to clearly convey that information. This study will fill that gap.


Clinical Trial Description

Cancer burden is increasing in Singapore. As Singapore's population increases, so too does the incidence of cancer. A total of 61,519 incident cancer cases were diagnosed in Singapore between 2010-2014. High disease incidence has resulted in a greater fiscal burden for patients and the health system as cancer patients consume a disproportionate amount of healthcare resources.Despite improved treatments, cancer related mortality is high; cancer has overtaken diseases of the circulatory system (including ischemic heart disease) to become the leading cause of death in Singapore. It now accounts for nearly 30% of all deaths. Given these sobering statistics, policy makers are struggling with how best to cost-effectively accommodate the health care needs of this vulnerable population.

Many Patients Want to Know Their Prognosis. A recent systematic review showed that the majority of cancer patients (and their caregivers) expressed a desire for prognostic information and how it varies by treatment choice. However, the preferred style for receiving that information varied. One study showed that nearly 80% of patients wanted a qualitative prognosis (i.e. will they die from the disease) whereas only half wanted a quantitative prognosis (i.e. how long they will survive). Regardless of how the information is conveyed, studies have shown that patients who discuss prognosis with their physicians have a better understanding of the disease trajectory, are more likely to pursue comfort-oriented over life-prolonging care, and are better able to cope with their illness and clarify priorities and goals.

Physicians Often Withhold Prognostic Information. Despite many patient's preferences for prognostic information, the literature reveals a reluctance among physicians' to disclose information about prognosis when it is poor.8 Physicians often find it easier to offer aggressive treatments rather than engage in challenging end-of-life discussions.In Singapore, as with other Asian countries, physicians often collude with caregivers to hide prognostic information from patients. Even when discussed, patients may fail to understand and recall the information presented because of unfamiliar terminology, such as "median survival" or "relative/absolute risk reduction".In many cases, patients are reluctant to ask additional questions about prognoses even though they may desire this information.

Systematic bias in Prognosis. If lack of communication were the sole cause of poor prognostic information, then patient's beliefs about their prognosis would be associated with high variance, but not necessarily biased in a particular direction. Yet, most patients with advanced cancer state unrealistic expectations about the benefits of treatment, believe that their cancer is curable and over-estimate their predicted life expectancy.This bias results from several factors. First, patients who are managing their symptoms well, have strong social and family support, and/or are happy with other aspects of their care may suffer from a form of halo effect, which is a cognitive bias where their chances of a cure are positively influenced by these other properties.Second, patients diagnosed with cancer at early stages are often (rightly) presented with optimistic chances of survival. For those whose cancer progresses, even when informed with the new information, they are less likely to fully update their prior beliefs as compared to someone first diagnosed at a later stage. This lack of complete updating is consistent with confirmatory bias where people give disproportionately less consideration to new information that does not conform to their prior expectations.However, even those newly diagnosed at a later stage are likely to be overly optimistic about their chances for a cure.Although there are negative consequences from this form of optimism bias, such as overtreatment, it can also be part of a successful coping strategy.In fact, the benefits of 'forcing' patients to understand their prognosis may not be worth the costs due to the additional emotional distress it may inflict. This may hold true even if hope leads patients to undergo costly and burdensome treatments with a low probability of success. However, it is still important to understand the extent of divergence between hope and beliefs, the level and type of information that patients would like to receive and how best to convey that information.

Discerning Hope from Beliefs. To discern whether or not patients have an accurate understanding of their prognosis requires disentangling what they believe will occur from what they hope will occur. There are two promising strategies that allow for producing these estimates. The first strategy is to ask patients about their own beliefs, and then to compare their responses to how they believe their physician would respond. If their physician has provided them with accurate prognostic information, then eliciting the physicians' frame should allow for a more accurate assessment of beliefs less likely to be confounded by hope. Consistent with this hypothesis, a study of advanced cancer patients in the US reveals that the degree of prognostic discordance between physicians and patients decreases when patients are asked to respond using the physician's frame of reference.Yet, a second study using a similar approach still found very high discordance, which suggests either poor patient-physician communication or that using the physician's frame does not entirely reduce the confounding of hope and beliefs.

A second approach is to offer what economists term 'an incentive compatible strategy. Consistent with the idea that 'ignorance is bliss', even if patients are aware of their prognosis, many may prefer to express false hope rather than state the truth about their condition. In economic terms their utility (a measure of happiness) is higher when they express false hope. To encourage these individuals to state their true beliefs, they can be offered a reward such that the utility of expressing their true beliefs plus the reward is greater than the utility when they express false hope. Because the reward makes it in the best interest of the participant to reveal his/her beliefs truthfully, such incentive compatible approaches are sometimes known as truth serums.It is often operationalized by stating that the reward will be provided if the responses match the views of a professional (i.e., their physician) or the best evidence from the literature. For example, in one US study, college students were asked to rank the mortality risk from 12 different causes of death. Those offered a reward for correct rankings were more likely to rank the mortality risks accurately for their own age group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03325218
Study type Observational
Source Duke-NUS Graduate Medical School
Contact
Status Active, not recruiting
Phase
Start date April 1, 2018
Completion date August 31, 2021

See also
  Status Clinical Trial Phase
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03994601 - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01393990 - A Study of LY2228820 in Participants With Advanced Cancer Phase 1
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT04121676 - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03674567 - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Phase 1/Phase 2
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A
Completed NCT02778126 - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer Phase 1
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT02245204 - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01583777 - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer Phase 1